Survodutide
vs Retatrutide.
Compare survodutide and retatrutide by dual versus triple agonism, Phase 3 results, liver evidence, tolerability context, and approval status.
Also searched as BI 456906 vs Retatrutide · dual agonist vs triple agonist · liver fat comparison
Survodutide vs Retatrutide: What is the difference?
Survodutide and retatrutide are different investigational once-weekly obesity programs, and no head-to-head trial has compared them. Survodutide activates glucagon and GLP-1 receptors, while retatrutide also activates the GIP receptor. Both now have Phase 3 obesity results, but the percentages came from separate trials with different durations, dose strategies, populations, estimands, and placebo responses. Survodutide also has a dedicated liver-focused development record. Neither program is approved for marketing, and the current evidence cannot establish which drug is better for an individual.
See the useful differences first.
Start with identity, current US status, trial coverage, and the evidence relationship. Then carry the exact pair into a country-aware workspace without losing either record.
Survodutide
Investigational - not approved for marketing
- Route
- Once-weekly subcutaneous injection
- Registry
- 31 matched NCT records
- Sponsor
- Boehringer Ingelheim + Zealand Pharma
Retatrutide
Investigational - not FDA approved
- Route
- Once-weekly subcutaneous injection
- Registry
- 34 matched NCT records
- Sponsor
- Eli Lilly and Company
Survodutide vs Retatrutide: how direct is the evidence?
No participant in the cited sources was randomized between Survodutide and Retatrutide. Identity, mechanism, route, trial design, and regulatory status can be compared. Subtracting percentages from separate studies would create a treatment effect the evidence did not test.
Survodutide
Glucagon + GLP-1 receptor dual agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 program active and reporting
- Status
- Investigational - not approved for marketing
Two evidence records, no shared randomization.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
No randomized head-to-head trialRetatrutide
GIP + GLP-1 + glucagon receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 program reporting results
- Status
- Investigational - not FDA approved
The current exact-intervention dataset contains 268 unique NCT records across 13 tracked investigational programs. Counts describe registry coverage, not comparative evidence strength.
matched NCT records
- Recruiting
- 3
- Results posted
- 3
- Recruiting site observations
- 774
matched NCT records
- Recruiting
- 2
- Results posted
- 2
- Recruiting site observations
- 450
Compare the named molecules, active components, sponsors, and receptor strategies.
Compare the studied route, frequency, development phase, and exact program record.
Compare exact approvals, applications, and investigational status in the jurisdiction being checked.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
Use only adverse-event evidence reported for the cited protocol. Separate studies cannot establish which program is safer.
No group result, receptor count, route, approval milestone, or chart position predicts the best choice for one person.
Check both programs in the same market.
Approval, trial activity, product registration, pharmacy rules, and seller authority are country specific. Open both records before treating a status from one market as valid in another.
Answer the question without inventing a winner.
Each answer keeps route, mechanism, development stage, and trial result attached to the evidence that produced the fact.
Is Survodutide better than Retatrutide?
No head-to-head trial establishes Survodutide or Retatrutide as better. Survodutide combines glucagon and GLP-1 receptor activity and has dedicated obesity and liver-focused development. Retatrutide adds GIP receptor activity and has reported a larger maximum percentage in a separate Phase 3 obesity trial. Different protocols, doses, durations, populations, and placebo responses prevent that difference from becoming a comparative result.
Does Survodutide reduce liver fat?
Survodutide has produced liver-fat and MASH signals in dedicated studies, but the endpoint and population must stay attached to the exact protocol. A relative reduction in liver fat, a threshold response such as at least 30%, and a fibrosis or MASH endpoint are not interchangeable. Those findings do not establish superiority over Retatrutide or predict an individual's result.
Survodutide
Glucagon + GLP-1 receptor dual agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 program active and reporting
- Status
- Investigational - not approved for marketing
- Featured trial anchors
- NCT06066515 · NCT06066528 · NCT06077864 · NCT06309992
Retatrutide
GIP + GLP-1 + glucagon receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 program reporting results
- Status
- Investigational - not FDA approved
- Featured trial anchors
- NCT05929066 · NCT05931367 · NCT05882045
Compare the field, then read the limit.
Both molecules include glucagon receptor agonism while retatrutide adds GIP activity. Quick summaries often turn that receptor count into a potency ranking or compare the largest percentage from each trial as if the studies shared one protocol. The useful comparison instead separates mechanism, treatment-regimen and efficacy estimands, trial duration, liver-focused evidence, adverse-event discontinuation, and regulatory status.
| Field | Survodutide | Retatrutide | How to interpret it |
|---|---|---|---|
| Receptor design | Glucagon and GLP-1 receptor dual agonist | GIP, GLP-1, and glucagon receptor triple agonist | The additional GIP pathway distinguishes retatrutide, but receptor count alone cannot establish clinical superiority. |
| Phase 3 treatment-regimen estimate | 13.0% at 76 weeks for 6.0 mg in SYNCHRONIZE-1 | 25.0% at 80 weeks for 12 mg in TRIUMPH-1 | These estimates include treatment discontinuation effects but still come from separate randomized trials with different placebo responses. |
| Phase 3 efficacy estimate | Up to 16.6% at 76 weeks in SYNCHRONIZE-1 | 28.3% at 80 weeks for 12 mg in TRIUMPH-1 | The maxima orient readers to each program and cannot be used as a randomized head-to-head result. |
| Liver-focused record | Dedicated MASH, MASLD, liver-fat, and fibrosis development program | Obesity program includes metabolic and liver-related measures but is not the same trial program | A dedicated disease program answers a different question from overall weight loss and should not be converted into a general winner claim. |
| Current status | Phase 3 active and reporting; not approved for marketing | Phase 3 active and reporting; not FDA approved | Completed or reported Phase 3 results do not establish submission, approval, launch timing, price, coverage, or availability. |
Why the headline numbers do not name a winner.
In SYNCHRONIZE-1, the 6.0 mg survodutide group had 13.0% mean weight loss at week 76 under the treatment-regimen estimand, while the sponsor also reported up to 16.6% under an efficacy estimand. In TRIUMPH-1, the 12 mg retatrutide group had 25.0% at week 80 under the treatment-regimen estimand and 28.3% under an efficacy estimand. Even matching estimand labels do not create a direct comparison because randomization occurred within each separate trial, not between the two drugs.
Keep the comparison honest.
- 01
Keep treatment-regimen and efficacy estimates attached to the exact dose, duration, population, placebo response, and trial that produced them.
- 02
Treat survodutide's liver-focused evidence as its own clinical question, not as proof that it is better for weight loss or for every patient group.
- 03
Do not treat a vial or listing using either investigational name as the sponsor's clinical material, an approved product, or a legitimate treatment route.
A country-specific approval, clinical trial, or matching name does not authenticate an online product or establish access elsewhere. This page contains no treatment recommendation, buying route, personal-use protocol, or affiliate link.
Open the safety and status guide →